3/16/2011 | CVPF | Pro-Pharmaceuticals files $50 million shelf for stock and preferreds
|
1/27/2011 | PP | Pro-Pharmaceuticals revises terms of series B-1, series B-2 preferreds
|
1/14/2011 | PP | Pro-Pharmaceuticals places additional $130,000 convertible preferreds
|
1/6/2011 | PP | Pro-Pharmaceuticals seals $2.12 million preferreds private placement
|
12/10/2009 | PP | New Issue: Pro-Pharmaceuticals raises another $325,000 in 12% preferreds placement
|
11/4/2009 | PP | New Issue: Pro-Pharmaceuticals raises another $310,000 in 12% preferreds placement
|
10/6/2009 | PP | New Issue: Pro-Pharmaceuticals completes $325,000 tranche of 12% preferreds sale
|
7/6/2009 | PP | New Issue: Pro-Pharmaceuticals wraps $500,000 tranche of $6 million private placement of preferreds
|
5/19/2009 | PP | New Issue: Pro-Pharmaceuticals completes $900,000 tranche of $4.2 million preferreds sale
|
2/17/2009 | PP | New Issue: Pro-Pharmaceuticals concludes $1.8 million tranche of $6 million preferreds sale
|
2/15/2008 | PP | New Issue: Pro-Pharmaceuticals plans $3.75 million placement of shares
|
2/7/2008 | PP | New Issue: Pro-Pharmaceuticals negotiates $1.74 million placement of units
|
1/29/2008 | CV | Pro-Pharmaceuticals files $10 million shelf registration
|
1/28/2008 | SS | Pro-Pharmaceuticals' future questionable
|
11/14/2007 | PP | New Issue: Pro-Pharmaceuticals settles placement of units for $982,500
|
8/9/2007 | PP | Pro-Pharmaceuticals plans private placement of securities
|
7/2/2007 | PP | Pro-Pharmaceuticals cancels stock placement
|
6/19/2007 | PP | New Issue: Pro-Pharmaceuticals secures $2.71 million from stock placement
|
3/21/2007 | CV | Pro-Pharmaceuticals to issue shares for $3.9 million 7% convertibles
|
11/13/2006 | BT | Pro-Pharmaceuticals estimates cash is sufficient to fund operations through June 2007
|
9/28/2006 | BTPP | Pro-Pharmaceuticals to make next convertible debentures payment in cash
|
8/30/2006 | BT | Pro-Pharmaceuticals to start dosing in three new Davanat trials
|
8/14/2006 | BT | Pro-Pharmaceuticals quarterly net loss improves, R&D spending up 20%
|
7/25/2006 | BT | Pro-Pharmaceuticals seeks OK for phase 2 colorectal cancer trial
|
5/24/2006 | BT | Pro-Pharmaceuticals, Mt. Sinai School of Medicine to collaborate in liver fibrosis research
|
4/5/2006 | BT | Pro-Pharmaceuticals' preliminary phase 2 data show partial tumor response with Davanat plus 5-FU
|
3/30/2006 | BT | Pro-Pharmaceuticals completes enrollment in stage 1 of phase 2 colorectal cancer trial
|
3/17/2006 | BT | Pro-Pharmaceuticals says Davanat study accepted as abstract for American Society of Oncology meeting
|
3/16/2006 | BT | Pro-Pharmaceuticals awarded patent for chemotherapeutic carbohydrate compound
|
3/10/2006 | BT | Pro-Pharmaceuticals reports $1.75 million 4Q net loss, says operations funded through June 2007
|
2/24/2006 | BT | Pro-Pharmaceuticals updates Davanat trials at cancer drug research conference
|
2/16/2006 | PP | Market Commentary: Idaho General Mines digs up $30 million from PIPE; Wave Systems raises $4.46 million from stock sale
|
2/15/2006 | BT | Market Commentary: Pfizer peddling ¥50 billion bonds; Amgen up out of chute; Adolor at bat; Ranbaxy taps convertibles market
|
2/15/2006 | PP | Market Commentary: Pro-Pharmaceuticals gears up to settle $10 million debenture deal; biotech sector dominates PIPEs
|
2/15/2006 | BTPP | New Issue: Pro-Pharmaceuticals to close $10 million sale of convertibles
|
2/2/2006 | BT | Pro-Pharmaceuticals gets compassionate use for Davanat/5-FU to treat patient with bile duct cancer
|